Related Experiment Videos
Inhaled glucocorticoids in children: A favourable therapeutic index
1Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Canada. imcniven@cc.umanitoba.ca
Insights
Inhaled glucocorticoids effectively manage persistent asthma in children by reducing symptoms and exacerbations. Low doses are safe, offering a favorable risk-benefit profile for long-term use.
Area of Science:
- Pediatric Pulmonology
- Pharmacology
Background:
- Persistent asthma significantly impacts children's quality of life.
- Asthma management often requires long-term medication.
Purpose of the Study:
- To evaluate the efficacy and safety of inhaled glucocorticoids in children with persistent asthma.
- To determine the risk-benefit ratio of inhaled glucocorticoids at minimal effective doses.
Main Methods:
- Review of clinical data on inhaled glucocorticoid use in pediatric asthma.
- Analysis of symptom control, exacerbation rates, and adverse events.
Main Results:
- Inhaled glucocorticoids reduce asthma symptoms and exacerbations.
- They decrease the need for rescue bronchodilators and improve lung function.
- Low doses minimize systemic adverse events, showing a favorable risk-benefit ratio.
Conclusions:
- Inhaled glucocorticoids are a safe and effective treatment for persistent childhood asthma.
- Minimal effective doses provide significant benefits with minimal risks.
Abstract:
In children with persistent asthma, inhaled glucocorticoids decrease symptoms and exacerbations, decrease the need for rescue bronchodilator medications, improve airway patency and reduce airway hyperresponsiveness. When administered in the lowest doses that prevent symptoms and eliminate the need for supplemental courses of oral glucocorticoids, they are unlikely to cause clinically important systemic adverse events. Inhaled glucocorticoids have a favourable risk to benefit ratio in this population.